Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4983637 | 0.92 | P2RX7 (0.47) | SMN1; SMN2HSD11B1MEN1USP2KMT2A | |
| SCHEMBL4988113 | 0.91 | P2RX7 (0.50) | SMN1; SMN2MEN1USP2KMT2ATSHR | |
| SCHEMBL4982547 | 0.90 | TSHR (0.43) | SMN1; SMN2MEN1USP2KMT2ATSHR | |
| SCHEMBL4986137 | 0.90 | TSHR (0.43) | SMN1; SMN2TSHRP2RX7ALDH1A1LMNA | |
| SCHEMBL4982679 | 0.90 | TSHR (0.43) | SMN1; SMN2USP2TSHRP2RX7ALDH1A1 | |
| SCHEMBL4985518 | 0.90 | TSHR (0.41) | SMN1; SMN2TSHRP2RX7ALDH1A1LMNA | |
| SCHEMBL4992206 | 0.90 | MEN1 (0.51) | SMN1; SMN2HSD11B1MEN1USP2KMT2A | |
| SCHEMBL14272516 | 0.88 | TSHR (0.56) | HSD11B1MEN1KMT2ATSHRPTPN1 | |
| SCHEMBL4988614 | 0.88 | TSHR (0.41) | SMN1; SMN2MEN1USP2KMT2ATSHR | |
| SCHEMBL5011770 | 0.88 | P2RX7 (0.42) | SMN1; SMN2MEN1KMT2ATSHRP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | SMN1; SMN2 4369/4885HSD11B1 3494/4885MEN1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.